人工智能优化成人PLA2R1相关膜性肾病的利妥昔单抗治疗
该研究基于92份成人原发性膜性肾病患者第3个月的血清样本,用机器学习预测利妥昔单抗剂量不足风险。模型纳入年龄、性别、体表面积、抗PLA2R1抗体滴度及第0天和第15天的血清白蛋白与肌酐,训练集与测试集的准确率分别为79.4%和79.2%。预测剂量不足风险高的患者缓解时间更长、所需累积剂量更高。
要点
- 第3个月血清利妥昔单抗水平<2 μg/ml提示剂量不足,是治疗失败的危险因素。
- 模型纳入年龄、性别、体表面积、抗PLA2R1抗体及第0天和第15天的白蛋白、肌酐。
- 预测剂量不足风险高的患者缓解更慢、所需利妥昔单抗累积剂量更高。
核心结论
- 机器学习算法可预测成人原发性膜性肾病患者利妥昔单抗剂量不足风险,并可能支持早期强化方案以提高缓解可能性。
研究设计与样本
- 研究测量92份成人原发性膜性肾病患者第3个月的利妥昔单抗浓度,按75%训练集和25%测试集划分。
- 采用前向-后向机器学习方法在训练集确定预测剂量不足的最佳变量组合,并在测试集验证。
- 以10折交叉验证评估准确率、敏感度和特异度。
主要发现
- 预测剂量不足的最佳变量组合包括年龄、性别、体表面积、第0天抗PLA2R1抗体滴度、第0天和第15天血清白蛋白及第0天和第15天血清肌酐。
- 准确率、敏感度、特异度在训练集分别为79.4%、78.7%、81.0%,在测试集分别为79.2%、84.6%、72.7%。
- 两个数据集中算法表现均显著优于随机(P < 0.05)。
- 初始预测剂量不足概率高的患者缓解时间更长,达到缓解所需利妥昔单抗累积剂量更高。
关键数值与推荐
- 利妥昔单抗剂量不足定义为第3个月血清水平<2 μg/ml。
- 模型预测变量包括年龄、性别、体表面积、第0天抗PLA2R1抗体滴度、第0天和第15天血清白蛋白及肌酐。
- 训练集准确率79.4%、敏感度78.7%、特异度81.0%;测试集准确率79.2%、敏感度84.6%、特异度72.7%。
临床怎么用
- 对拟接受利妥昔单抗的成人原发性膜性肾病患者,可依据上述基线及第15天指标评估剂量不足风险。
- 对预测高剂量不足风险者,可考虑早期强化利妥昔单抗方案以提高缓解可能性。
局限性
- 样本量较小,仅92份血清,训练集与测试集划分后每集样本有限。
- 研究为单次第3个月浓度测量,预测模型的外部验证尚未报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Rituximab is a first-line treatment for membranous nephropathy. Nephrotic syndrome limits rituximab exposure due to urinary drug loss. Rituximab underdosing (serum level <2 μg/ml at month-3) is a risk factor for treatment failure. We developed a machine learning algorithm to predict the risk of underdosing based on patients' characteristics at rituximab infusion. We investigated the relationship between the predicted risk of underdosing and the cumulative dose of rituximab required to achieve remission. METHODS: Rituximab concentrations were measured at month-3 in 92 sera from adult patients with primary membranous nephropathy, split into a training (75%) and a testing set (25%). A forward-backward machine-learning procedure determined the best combination of variables to predict rituximab underdosing in the training data set, which was tested in the test set. The performances were evaluated for accuracy, sensitivity, and specificity in 10-fold cross-validation training and test sets. RESULTS: The best variables combination to predict rituximab underdosing included age, gender, body surface area (BSA), anti-phospholipase A2 receptor type 1 (anti-PLA2R1) antibody titer on day-0, serum albumin on day-0 and day-15, and serum creatinine on day-0 and day-15. The accuracy, sensitivity, and specificity were respectively 79.4%, 78.7%, and 81.0% (training data set), and 79.2%, 84.6% and 72.7% (testing data set). In both sets, the algorithm performed significantly better than chance (P < 0.05). Patients with an initial high probability of underdosing experienced a longer time to remission with higher rituximab cumulative doses required to achieved remission. CONCLUSION: This algorithm could allow for early intensification of rituximab regimen in patients at high estimated risk of underdosing to increase the likelihood of remission.
引用
- Destere A, Teisseyre M, Merino D, et al. Optimization of Rituximab Therapy in Adult Patients With PLA2R1-Associated Membranous Nephropathy With Artificial Intelligence. Kidney Int Rep. 2023. PMID: 38312797. doi:10.1016/j.ekir.2023.10.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。